Loading...
•
Mar 31
ICU Medical Q1 2025 Earnings Report
Reported first quarter 2025 results
Key Takeaways
ICU Medical reported improved results in the first quarter of 2025 compared to the prior year, with increased total revenues, gross profit, and a significantly reduced net loss. Adjusted EBITDA and adjusted diluted EPS also showed strong growth.
Total revenues for Q1 2025 increased to $604.7 million from $566.7 million in Q1 2024.
GAAP gross profit rose to $210.1 million in Q1 2025 from $185.2 million in the prior year period.
GAAP net loss improved significantly to $(15.5) million in Q1 2025 compared to $(39.5) million in Q1 2024.
Adjusted diluted earnings per share increased to $1.72 in Q1 2025 from $0.96 in Q1 2024.
ICU Medical
ICU Medical
ICU Medical Revenue by Segment
Revenue by Segment
Consumables Revenue
CapyFin.comInfusion Systems Revenue
CapyFin.comVital Care Revenue
CapyFin.com Forward Guidance
First quarter results were generally in line with expectations.
Positive Outlook
- Management expressed satisfaction with the Q1 performance being in line with expectations.
- Continued focus on providing quality, innovation, and value to customers.
- Global leadership position in key product areas.
- Team is focused on serving hospital, alternate site, and home care settings.
- Expectations regarding the future and financial outlook for 2025.
Challenges Ahead
- Risks from doing business in foreign countries, including tariffs and trade barriers.
- Ability to compete successfully.
- Decreased demand for products.
- Cost volatility or loss of supply of raw materials.
- Inflation, tariffs, and foreign currency exchange rates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income